Atb Cap Markets Estimates Organigram’s Q3 Earnings (TSE:OGI)

Organigram Holdings Inc. (TSE:OGI) – Investment analysts at Atb Cap Markets lowered their Q3 2025 earnings estimates for Organigram in a research note issued on Tuesday, February 11th. Atb Cap Markets analyst F. Gomes now anticipates that the company will post earnings of ($0.03) per share for the quarter, down from their previous estimate of ($0.02). The consensus estimate for Organigram’s current full-year earnings is $0.16 per share. Atb Cap Markets also issued estimates for Organigram’s Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at $0.00 EPS.

OGI has been the subject of several other research reports. ATB Capital reduced their price objective on shares of Organigram from C$5.25 to C$3.50 in a research note on Tuesday, December 17th. Canaccord Genuity Group reduced their price objective on shares of Organigram from C$3.60 to C$3.15 and set a “speculative buy” rating for the company in a research note on Monday, December 9th.

Organigram Price Performance

Shares of TSE:OGI opened at C$1.81 on Friday. The company has a 50 day moving average of C$2.23 and a 200 day moving average of C$2.31. The stock has a market cap of C$223.61 million, a P/E ratio of -3.83, a P/E/G ratio of 0.42 and a beta of 1.13. Organigram has a 12 month low of C$1.80 and a 12 month high of C$3.95. The company has a current ratio of 3.36, a quick ratio of 2.62 and a debt-to-equity ratio of 3.07.

About Organigram

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.